The funds will enable Atox Bio to initiate a late stage clinical study of AB103, for the treatment of necrotising soft tissue infections (NSTI), commonly referred to as the "flesh eating bacteria" and other severe infections. The study is expected to start in the second half of 2015.
AB103, an immunomodulator licensed from Yissum, the technology transfer company of the Hebrew University In Jerusalem, is a peptide that offers a unique approach in the treatment of infectious diseases by modulating, but not inhibiting, the host immune system.
Known as the Startup Nation, Israeli startups have now taken their expertise in innovation and technology to create revolutionary tools for the blind and visually impaired, two of them from Hebrew university researchers.
The next interim results expected at Q3 2015, following 2 years of treatment; final results expected at Q3 2016, following 3 years of treatment
With Michael Brandwein’s work on bacterial biofilm disruption, fresh fruits and vegetables can once again be safe
Take a look at some of the leading new Agricultural Technologies that will help feed the world in the coming decades.
The next innovation that will feed you: Introducing the future of agriculture
Ever notice how a spilled drop of coffee spreads into a ring stain on your shirt? The particle-filled liquid flows outward from the drop, leaving the particles on the rim of the ring as the liquid evaporates. This phenomenon posed big problems for printers. How do you keep drops of ink in place? Then Hebrew University Prof. Shlomo Magdassi realized it could actually provide a way to move the industry toward a fantastic future in functional printing.
Avi Hasson, Chief Scientist of Israel’s Ministry of Economy, said at the award ceremony: “Qlight Nanotech encompasses a winning combination of outstanding technology originating from the Hebrew University together with a leading international partner".
Yissum displays some of the most exciting advances at NanoIsrael 2014 in Tel Aviv, an event that drew thousands from 30 countries.
Mobileye is planning an IPO at a colossal company valuation of $2.5-3 billion, according to financial news website Calcalist. If that is the case, Mobileye, which specializes in the development of Advanced Driver Assistance Systems (ADAS) for motor-vehicles, will offer up the largest ever IPO made by an Israeli company on NASDAQ. According to the report, the Israeli founders of Mobileye will attempt to raise $500 million at a company valuation of $2.5-3 billion.
If the eyes don’t work properly, the ears are an appropriate substitute for vision, according to Prof. Amir Amedi
These inks, developed by Prof. Shlomo Magdassi from the Casali Institute of Chemistry, allow printing nanoscale electronic circuits, cheap flexible displays, smart labels and posters and even active clothing.
Demonstration at AIPAC of one of Yissum's AMAZING technologies that allows blind people to HEAR colors.
Professor emeritus Marta Weinstock-Rosin at the Hebrew University of Jerusalem’s pharmacology department has spent years studying drug treatments for degenerative diseases of the central nervous system.
Her research there ranged from how salt raises blood pressure to developing drugs for Alzheimer’s, including rivastigmine (Exelon).
Yissum presents the pipeline of the future: This is where the Start Up Nation begins.
The promising technology is based on years of research at the Hebrew Univresity's Faculty of Agriculture, and was licensed to the company by Yissum.
The Hebrew University’s technology transfer company, Yissum, has applied for a patent for the treatment of some forms of depression by several specific microglia-stimulating drugs
Novel sodium-ion battery is an environmentally friendly, economic and efficient solution for a variety of applications including electric vehicles and stationary storage for renewable energies
Study was published in the prestigious Nature Communications Journal
The Jerusalem-based start-up said that half of the patients have already been enrolled in the Phase II clinical trial that will include 80 patients with newly diagnosed metastatic pancreatic cancer and have have yet to start chemotherapy. The trial includes two treatment groups of 40 subjects each. The control group is allocated to standard chemotherapy for pancreatic cancer, and the treatment group will receive TL-118 in addition to standard-of-care chemotherapy.
